{
    "nctId": "NCT01441947",
    "briefTitle": "Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer",
    "officialTitle": "A Phase II Trial of Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer With Involvement of Bone",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 68,
    "primaryOutcomeMeasure": "Bone Scan Response Rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Clear evidence of metastases to bone on isotope bone scan\n* Histologically or cytologically confirmed metastatic Estrogen-receptor-positive (ER+) and/or Progesterone-receptor-positive (PR+) and Human Epidermal Growth Factor Receptor (HER) 2 negative breast cancer\n* Received at least one prior line of hormonal or chemo-therapy for metastatic disease\n* must be post menopausal\n* Recovered from toxicities related to prior treatment, except alopecia, lymphopenia, or other non-clinically significant Adverse Events (AEs)\n* Life expectancy \\> 3 months\n* Adequate organ and marrow function\n* Sexually active fertile subjects and their partners must agree to use medically accepted methods of contraception\n* Able to lie flat for up to 45 minutes for imaging studies\n* Able to swallow capsules or tablets\n\nExclusion Criteria:\n\n* Pregnant or breast-feeding\n* Has experienced clinically-significant hematemesis or hemoptysis of \\> 0.5 teaspoons of red blood, or other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment\n* Untreated, symptomatic or uncontrolled brain metastasis requiring current treatment including steroids and anti-convulsants\n* more than 1 prior line of chemotherapy for treatment of metastatic breast cancer\n* prior treatment with fulvestrant\n* Requires concomitant treatment, in therapeutic doses, with anticoagulants such as warfarin or coumadin-related agents, thrombin or Factor Xa inhibitors, and antiplatelet agents (eg, clopidogrel)\n* Uncontrolled or significant intercurrent illness\n* Gastrointestinal disorders, particularly those associated with a high risk of perforation or fistula formation\n* Active infection requiring systemic treatment\n* Serious non-healing wound/ulcer/bone fracture\n* History of organ transplant\n* Concurrent uncompensated hypothyroidism or thyroid dysfunction\n* Previously-identified allergy or hypersensitivity to components of the study treatment formulation\n* Diagnosis of another malignancy, requiring systemic treatment, within the last 2 years, unless non-melanoma skin cancer, in-situ carcinoma of the cervix, or superficial bladder cancer",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}